In a patient who uses albuterol only as needed, would Breztri (budesonide/formoterol/glycopyrrolate) or AirSupra (albuterol) be appropriate for treating an asthma exacerbation?

AirSupra is the Appropriate Choice for This Patient

For a patient currently using only albuterol as needed, AirSupra (albuterol-budesonide combination) is the appropriate medication to reduce exacerbation risk, while Breztri is not indicated for asthma at all. 1

Why AirSupra is the Right Answer

AirSupra is FDA-approved specifically for as-needed treatment in asthma patients to both relieve bronchoconstriction AND reduce exacerbation risk 1. This directly addresses your patient's situation—someone relying solely on rescue medication without controller therapy.

The Evidence Supporting AirSupra

The most recent high-quality data from 2025 demonstrates that as-needed albuterol-budesonide reduced severe exacerbations by 47% compared to albuterol alone in patients with mild asthma (hazard ratio 0.53,95% CI 0.39-0.73, P<0.001) 2. Critically, 74.4% of participants in this trial were using SABA alone at baseline—exactly matching your patient's profile 2.

The annualized exacerbation rate dropped from 0.32 with albuterol alone to 0.15 with albuterol-budesonide, while simultaneously reducing systemic glucocorticoid exposure from 61.9 mg to 23.2 mg per year 2. This represents a 53% reduction in exacerbation risk while avoiding the burden of daily maintenance therapy.

Practical Dosing

• Dose: 2 inhalations (180 mcg albuterol/160 mcg budesonide total) as needed for symptoms 1
• Maximum: 6 doses (12 inhalations) per 24 hours 1
• Key advantage: Patients take medication only when symptomatic, improving adherence compared to daily controllers

Important Safety Considerations

Advise patients to rinse their mouth with water after each use to prevent oral candidiasis 1. Monitor for signs of worsening asthma control—if the patient needs AirSupra frequently or symptoms persist after use, this signals disease destabilization requiring treatment escalation 1.

Watch for cardiovascular effects in patients with underlying heart disease, and use caution in those with diabetes, hyperthyroidism, or seizure disorders 1.

Why Breztri is Wrong for Asthma

Breztri (budesonide/glycopyrrolate/formoterol) is FDA-approved only for COPD, not asthma. While recent 2026 research shows BGF reduces exacerbations in patients with uncontrolled asthma on medium-to-high dose ICS-LABA 3, this represents:

1. Off-label use in asthma
2. A medication for patients already failing ICS-LABA maintenance therapy—not someone on albuterol alone
3. A triple therapy requiring daily scheduled dosing, not as-needed use

Your patient needs to start with appropriate as-needed therapy (AirSupra), not jump to triple maintenance therapy designed for severe, uncontrolled disease.

The Paradigm Shift in Asthma Management

This recommendation aligns with the evolution away from SABA-only rescue therapy. The 2020 NAEPP guidelines acknowledge intermittent ICS dosing strategies, though they predate AirSupra's approval 4. The 2009 guidelines focused on traditional SABA plus ipratropium for acute exacerbations 5, but newer evidence demonstrates superior outcomes when combining the bronchodilator with an inhaled corticosteroid from the outset 2, 6.

The critical insight: Relying on SABA alone fails to address the inflammatory component driving exacerbations. AirSupra treats both bronchoconstriction and inflammation simultaneously with each rescue dose.

Common Pitfalls to Avoid

• Don't prescribe Breztri for asthma in a patient on SABA alone—it's the wrong medication for the wrong indication
• Don't continue albuterol-only therapy when evidence clearly shows increased exacerbation risk
• Don't assume the patient needs daily maintenance therapy first—as-needed ICS-LABA is now a validated strategy for mild asthma 2
• Don't forget to update the asthma action plan to reflect the new rescue medication dosing